Idorsia has a diversified clinical development pipeline in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders, and orphan diseases.

Status Compound Mechanism of Action Target Indication 
Phase 2       Aprocitentan* Endothelin receptor antagonist Resistant hypertension management
ACT-541468 Dual orexin receptor antagonist Insomnia
Clazosentan** Endothelin receptor antagonist Vasospasm associated with aneurysmal subarachnoid hemorrhage
Cenerimod S1P1 receptor modulator Systemic lupus erythematosus
Vamorolone*** Non-hormonal steriod modulator Duchenne muscular dystrophy
Phase 1b Lucerastat Glucosylceramide synthase inhibitor Fabry disease
Phase 1       ACT-246475 P2Y12 receptor antagonist Acute coronary syndrome
ACT-774312 CRTH2 receptor antagonist Asthma and allergy disorders
ACT-539313 Selective orexin 1 receptor antagonist Anxiety
ACT-709478 T-type calcium channel blocker Epilepsy


* Janssen Biotech are collaborating with Idorsia to jointly develop and to solely commercialize aprocitentan worldwide.

** Market registration studies are ongoing in Japan.

*** Idorsia has exclusive option to worldwide rights to ReveraGen’s Vamorolone